Punto Health secures €2.3 million seed round to expand AI-driven dementia care platform

The round was co-led by Shilling VC and Plus Partners, with additional backing from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest.

(L-R) Anna Muñoz-Farré, Co-founder & CEO at Punto Health; and Jack Eckersley, Co-founder & CTO at Punto Health | Image source: puntohealth.com
WT default author logo
Women's Tabloid News Desk

London-based healthtech startup Punto Health has raised €2.3 million in seed funding to support the development and rollout of its AI-powered dementia care platform across the UK and Spain. The round was co-led by Shilling VC and Plus Partners, with additional backing from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest.

Founded in 2023 by engineers Anna Muñoz-Farré and Jack Eckersley, Punto Health focuses on early detection and personalised support for people experiencing dementia and cognitive decline. The company plans to use the new funding to speed up product development and expand its commercial presence in key European markets.

Punto Health’s platform brings together patients, carers and clinicians through three connected products. PuntoTest is an AI-powered, speech-based digital assessment designed to identify signs of cognitive impairment. PuntoCare operates as a companion app, offering personalised care plans, cognitive exercises, nutrition guidance, symptom monitoring and broader wellbeing support. For healthcare professionals, PuntoClinic provides a dashboard that brings together patient-reported outcomes alongside biomarker data.

In Spain, PuntoTest has already been trialled in ten pharmacies across Barcelona, involving more than 1,500 participants aged 50 and above. The wider platform is currently being piloted with North London NHS Foundation Trust, NHS Oxleas Foundation Trust, and several hospitals in Barcelona. Punto Health said it is supporting more than 200 users aged between 60 and 90, who have collectively completed over 30,000 activities on the platform.

Dementia has a disproportionate impact on women. Women tend to live longer than men, making age-related cognitive decline more likely, while hormonal changes linked to menopause may also increase vulnerability. In addition, women provide around two-thirds of unpaid dementia care.

The platform has been co-designed and clinically validated in collaboration with Ace Alzheimer Centre Barcelona. The latest seed funding follows a €718,500 pre-seed investment secured earlier by the company.

Share:

Related Insights

Flouria Health raises €1.5 Million to expand women’s hormonal healthcare

Karen Hanlon named CEO of Highmark Health, becoming first woman to lead the organisation

Women’s Heart Alliance launches BARBRA, an AI Tool for Women’s Heart Health

eMed and The Female Quotient partner to advance women’s health

AMD crosses $1 Trillion as Lisa Su leads first Female-CEO company to the milestone

Hege Hansen and Stine Andreasen are rethinking women’s healthcare

Boundless Futures Foundation crosses $1.5M Milestone in funding for female entrepreneurs

Brigid Hughes appointed first female CEO of National Pharmacies